A Safety Profile Analysis of Siddha Polyherbal Formulation <i>Ēlāti Cūraṇam</i>
The present study was conducted to evaluate the safety profile of the Siddha formulation Ēlāti Cūraṇam (EC) for managing hypertension by assessing its acute and subacute toxicity in Wistar albino rats. Prior approval for the study was obtained from the Institutional Animal Ethics Committee (IAEC No: 04/321/PO/Re/S/01/CPCSEA-12/OCT-2018). For acute toxicity assessment, EC was administered as a single high dose of 2000 mg/kg, and the animals were observed for any immediate adverse reactions or signs of toxicity. For subacute toxicity evaluation, EC was given orally at doses of 100 mg/kg, 150 mg/kg, and 200 mg/kg over a prolonged period. Haematological and biochemical analyses were performed to monitor potential changes in organ function and blood parameters. The results revealed that EC was non-toxic at the acute dose of 2000 mg/kg, with no notable adverse effects observed on vital organs. Similarly, repeated administration at subacute doses did not cause significant alterations in haematological or biochemical parameters. No severe toxicological effects were detected in the organs or physiological indices assessed. Major Findings: The study found that Ēlāti Cūraṇam was non-toxic at a high acute dose of 2000 mg/kg and showed no significant adverse effects at subacute doses (100, 150, 200 mg/kg). Haematological, biochemical, and organ assessments confirmed its safety profile, supporting its traditional use for long-term management of hypertension. In conclusion, the findings suggest that EC is safe under both acute and subacute exposure conditions. These toxicological outcomes provide supportive evidence for the long-term use of EC and validate its traditional application from a safety standpoint.